Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues
We are witnessing a paradigm shift in drug development and clinical practice to fight the novel coronavirus disease (COVID-19), and a number of clinical trials have been or are being testing various pharmacological approaches to counteract viral load and its complications such as cytokine storm. How...
Main Authors: | Milo Gatti, Eleonora Turrini, Emanuel Raschi, Piero Sestili, Carmela Fimognari |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/8/738 |
Similar Items
-
Role of janus kinase inhibitors in the treatment of alopecia areata
by: Triyangkulsri K, et al.
Published: (2018-07-01) -
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
by: Dillon KAL
Published: (2021-06-01) -
Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
by: Michelle Le, et al.
Published: (2021-09-01) -
The Janus Kinase Inhibitor Ruxolitinib Prevents Terminal Shock in a Mouse Model of Arenavirus Hemorrhagic Fever
by: Mehmet Sahin, et al.
Published: (2021-03-01) -
Janus Associated Kinases Inhibitors in the Pharmacological Thera
by: Daniela Santos1, et al.
Published: (2017-01-01)